Figure 2. Sustained Disease Control With No Disease Worsening (Primary Outcome).

Adjusted difference in the rate of sustained disease control without disease worsening during 52 weeks of follow-up overall (the primary outcome) and by disease subgroup. Size of data markers is proportional to the number of patients in the group. Disease worsening was defined by disease-specific composite scores or a consensus about disease worsening between patient and physician leading to a major change in treatment. Disease worsening according to disease-specific composite measures was defined as follows: for rheumatoid arthritis and psoriatic arthritis, an increase from baseline of 1.2 points or more with a minimum score of 3.2 in the Disease Activity Score in 28 Joints; for spondyloarthritis, an increase from baseline of 1.1 points or more with a minimum score of 2.1 in the Ankylosing Spondylitis Disease Activity Score; for ulcerative colitis, an increase from baseline of more than 3 points with a score of 5 or greater in the Partial Mayo Score; for Crohn disease, an increase from baseline of 4 points or more and a score of 7 or greater in the Harvey-Bradshaw Index; and for psoriasis, an increase from baseline of 3 points or more and a score of 5 or greater in the Psoriasis Area and Severity Index. See Table 1 footnotes for detailed descriptions of the scales and eTable 1 in Supplement 2 for more information.